The Growth Hormone Deficiency (GHD) Reversal Trial: effect on final height of discontinuation versus continuation of growth hormone treatment in pubertal children with isolated GHD-a non-inferiority Randomised Controlled Trial (RCT).

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Growth hormone deficiency (GHD) is the commonest endocrine cause of short stature and may occur in isolation (I-GHD) or combined with other pituitary hormone deficiencies.

Who Took Part

The study group was 500 children.

The age groups tagged for this paper are children and adults.

Children will be randomised to either continue or discontinue GH therapy.

How the Study Was Run

The design is described as randomized, open-label, multicenter and pilot.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

What Was Measured

Topics PubMed links to this paper include Growth Hormone, Austria, Cost Savings, Critical Pathways and Drug Costs.

Author keywords: Adverse effects, Cost effectiveness, Discontinuation of growth hormone, Early puberty, Early retesting and Endocrine.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 500 children.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Trials), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.